[Clinical efficacy of 0.2% brimonidine in patients with open-angle glaucoma or ocular hypertension].
To evaluate the efficacy and safety of 0.2% brimonidine administered in patients with glaucoma or ocular hypertension. Twenty-five patients (41 eyes) with primary open-angle glaucoma or ocular hypertension were enrolled in this prospective study. Eye drops of 0.2% brimonidine were used twice daily for 6 months and the patients were examined every month after the treatment, including the trough intraocular pressure (IOP, IOP 12 h after 0.2% brimonidine was administrated) and the peak IOP (IOP 12 h after 0.2% brimonidine was administrated). The visual field was examined every three months. The use of 0.2% brimonidine significantly lowered the trough IOP and the peak IOP (P < 0.05). Every point of the IOP diurnal curve significantly decreased compared with the baseline (P < 0.05). The visual field had no significant change 3 months or 6 months after the treatment with 0.2% brimonidine. No serious systemic side effect was observed. Brimonidine is safe and effective in lowering IOP in glaucoma or ocular hypertension and is well tolerated.